LNAI logo

LUNAI BIOWORKS INC

LNAINASDAQ
🏆 #5271 by market capEarnings Nov 12US Equity
$0.24▼ $0.02 (−6.50%)
🌙 After hours$0.21▼ 10.59%Regular close · extended-hours price shown
🔔
Track LNAI
Get earnings, price moves & breaking news on Telegram
Track
24h▼ 6.5%
7d▼ 49.1%
14d▼ 73.9%
30d▼ 86.5%
ytd▼ 96.7%
1y▼ 96.9%
🏦Market Cap
$1M
Small Cap
📈Revenue Growth (YoY)
0.0%
Slowing
📊Gross Margin
-79.9%
Thin
💵FCF Margin
-10173.6%
Thin
⚖️P/S Ratio
20.6x
Expensive
Otter Score
—
Insufficient data

Trading Snapshot

Day Range
$0.20 – $0.25
52-Week Range
$0.20 – $13.28
Volume (shares)
498,870
Avg Volume (shares)
—
Shares Outstanding
4.5M
Next Earnings
2026-11-12

Fundamentals Snapshot

Annual Revenue
$51,992
Last Q Revenue
$31,050
P/E Ratio
-0.3
P/S Ratio
20.6x
EPS (TTM)
$-0.77
Dividend Yield
0.00%
Dilution (1yr)
+57.3%
LNAI logo

LUNAI BIOWORKS INC

LNAI
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$52K▲ +0.0% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$8M▼ −57.6% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$5.3B▲ +67070.4% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
4.6M▲ +57.3% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$375M▲ +$378M YoY
StockOtter · stockotter.space

About LUNAI BIOWORKS INC

Lunai Bioworks Inc. (LNAI), formerly operating as Renovaro, is now dedicated to leveraging artificial intelligence for the creation of advanced medical treatments and the strengthening of biological defense systems. A significant project currently underway is the development of its specialized "Neurotoxicity Intelligence Technology."

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)

Insufficient data for all five components.

💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
💧Dilution★★★★★
Overall Score
Insufficient data
—/100
Analyst data unavailable.

Latest News & Updates

PRNewsWire·6d ago

Lunai Bioworks Announces Receipt of Nasdaq Determination and Intention to Voluntarily Delist and Deregister

SACRAMENTO, Calif., Oct. 22, 2026 /PRNewswire/ -- Lunai Bioworks Inc. (Nasdaq: LNAI) (the "Company") announced that on October 21, 2026, it received a letter from the Listing Qualifications Department of The Nasdaq Stock

PRNewsWire·Sep 22

Lunai Bioworks (NASDAQ: LNAI) Expands Parkinson's Platform Through Exclusive Tanaist Agreement

Exclusive worldwide agreement adds human cellular validation to Lunai's AI-driven Parkinson's workflow, connecting patient-derived subtypes with disease mechanisms, biomarkers and therapeutic targets SACRAMENTO, Calif.,

PRNewsWire·Sep 16

Lunai Bioworks (Nasdaq: LNAI) Demonstrates AI Chemical-Risk Screening for Generative AI

5.1-fold enrichment using NIH Tox21 data validates structure-based AChE screening as OpenAI and Anthropic highlight growing dual-use AI risks SACRAMENTO, Calif., Sept. 16, 2026 /PRNewswire/ -- Lunai Bioworks, Inc. (Nasda

PRNewsWire·Sep 4

Lunai Bioworks (NASDAQ: LNAI) Issues Correction to Press Release Regarding Second Amended Complaint

Correction Updates a Reference Link; No Other Content in the Original Release Has Changed WILMINGTON, Del. and SACRAMENTO, Calif.

PRNewsWire·Aug 27

Lunai Bioworks (Nasdaq: LNAI) Names Six Broker-Dealers in Expanded Naked Short Selling Suit

Second Amended Complaint Alleges Securities Fraud and Market Manipulation Under Rule 10b-5 WILMINGTON, Del. and SACRAMENTO, Calif.

PRNewsWire·Aug 4

Lunai Bioworks (Nasdaq: LNAI) Signs Definitive Collaboration Agreement with BrainStorm Therapeutics; Initial Parkinson's Disease Data Readout Targeted for First Half of 2027

New BioSymetrics Inc. white paper and executed Master Collaboration Agreement establish an integrated roadmap spanning AI-driven patient stratification, human translational validation, biomarker development, and pharmace